BioSpace News Archive

BD, a leading global medical technology company, announced that it will report financial results for its second quarter of fiscal year 2023 on Thursday, May 4, 2023.

AbCellera (Nasdaq: ABCL) will announce its first quarter 2023 financial results on Thursday, May 4, 2023, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day.

Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it will report first quarter 2023 financial results after the market closes on Thursday, May 4, 2023.

IQVIA Holdings Inc. will announce its first-quarter 2023 financial results before the market opens on Thursday, April 27, 2023.

Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its first-quarter 2023 financial results on Thursday, April 27, 2023 at 7:30 a.m. Central Time.

Aadi Bioscience, Inc. (NASDAQ: AADI) today announced that it will present three posters at the American Association for Cancer Research Annual Meeting (AACR) 2023, taking place April 14-19, 2023, in Orlando, FL.

Carisma Therapeutics Inc. (Nasdaq: CARM), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the Company will participate at several conferences in April 2023.

Rigel Pharmaceuticals, Inc. announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the Compensation Committee of Rigel’s Board of Directors and granted as an inducement material to employees’ entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635.

Medicure Inc., a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, reported its results from operations for the quarter and year ended December 31, 2022.

Moderna, Inc. and Merck announced that mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with KEYTRUDA, Merck’s anti-PD-1 therapy, has been granted Priority Medicines scheme designation by the European Medicines Agency for the adjuvant treatment of patients with high-risk stage III/IV melanoma following complete resection.